Determining Biotech Valuations
This article was originally published in Start Up
Michael Lytton, a General Partner at Oxford Bioscience Partners, discusses how venture capital funds determine appropriate valuations for biotech companies in which they decide to invest.
You may also be interested in...
What makes a health care VC stand out in the minds of entrepreneurs? According to a first-of-its-kind survey by Windhover, PricewaterhouseCoopers, Wilson Sonsini, and Applied Information Networks, the answer is value-added services. Entrepreneurs prize VCs who assist them, pre-financing, with constructive feedback and sharing of due diligence results. VCs do pretty well here. But they do less well on the more important post-financing criteria: helping their portfolio companies secure additional financing and recruit customers, partners, and employees.
Our VC correspondent details the 10 most common mistakes his colleagues make in investing in biotech--from investing in dataless hypothesis to firing management too soon (or too late).
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.